Anti-cancer effects of lucidadiol against malignant melanoma cells

Melanoma is one of the most aggressive and lethal skin cancers. Lucidadiol is a triterpenoid isolated from Ganoderma lucidum and is known to have various biological functions, including antibacterial effects. However, the anti-cancer effects and mechanism of action of lucidadiol in malignant melanom...

Full description

Saved in:
Bibliographic Details
Published in:Applied biological chemistry 2021, 64(5), , pp.1-10
Main Authors: Shin, Seong-Ah, Lee, Jun Seob, Joo, Byeong Jun, Ryu, Gyoungah, Han, Minjoo, Kim, Huiji, An, Jangeun, Koo, Man Hyung, Youn, Ui Joung, Lee, Jun Hyuck, Park, Hyun Ho, Lee, Chang Sup
Format: Article
Language:English
Subjects:
AKT protein
Antibacterial activity
Anticancer properties
Antiinfectives and antibacterials
Apoptosis
Applied Microbiology
Biological Techniques
Bioorganic Chemistry
Cancer
Cell viability
Chemical compounds
Chemistry
Chemistry and Materials Science
MAP kinase
Melanoma
Pharmacology
Skin cancer
농학
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Melanoma is one of the most aggressive and lethal skin cancers. Lucidadiol is a triterpenoid isolated from Ganoderma lucidum and is known to have various biological functions, including antibacterial effects. However, the anti-cancer effects and mechanism of action of lucidadiol in malignant melanoma are unknown. In this study, lucidadiol significantly reduced B16 melanoma cell viability in a dose- and time-dependent manner. In addition, lucidadiol induced apoptosis and suppressed cell mobility in B16 melanoma cells. Moreover, our findings revealed that lucidadiol remarkably downregulated phospho-Akt/ERK/JNK, but not p38. Taken together, our results suggest that lucidadiol could exerts its anti-cancer effects by inducing apoptosis via modulation of the Akt/MAPK pathway. Therefore, lucidadiol may be a potential cancer therapeutic agent for malignant melanoma.
ISSN:2468-0834
2468-0842
DOI:10.1186/s13765-021-00647-w